Clinical Trials Browser

Biliary Tract Neoplasms × tislelizumab × 90 days × Clear all

NCT05254847 2026-01-20

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms